BioSolution Designs and RoosterBio Announce Collaboration on Genetically Modified MSCs for Biotherapeutic Development
Summary
Both teams have proven capabilities to deliver engineered therapies that possess a favorable global regulatory profile. Dr. Thomas D. Reed, CEO of BSD, commented on the partnership, saying, "Mesenchymal stem cells represent a major untapped resource with broad therapeutic utility, from regenerative medicine to treating rare diseases. Understanding all too well that The Product is the Process, we are thrilled to collaborate with RoosterBio, whose raison detre revolves around controlling all aspects of scalable cGMP manufacturing and characterization of human MSCs and MSC-derived exosomes. With optimized, scalable processes, Type II Master Files, and cGMP products, we have enabled therapeutic programs to traverse their path to clinical translation in under one year. RoosterBio is driven by clients success and creating a world where safe and effective regenerative medicines are rapidly developed and widely available on a global scale.